M28 Capital Management LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), M28 Capital Management LP reported 9 stock positions worth $47.2 million. Its top holding was Wave Life Sciences (WVE) at 56.5% of the portfolio, followed by Invivyd (IVVD, 17.1%) and TG Therapeutics (TGTX, 10.3%). Its holdings were unchanged from Q1 2026.
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001807489
- Portfolio Value
- $47.2M (Q2 2026)
- SEC Filing
- 0000902664-26-003441 ↗ filed Aug 13, 2026
Holdings Value
Holdings 9 stocks · $47.2M
| WVE Wave Life Sciences Ltd. | 56.53% | 4,588,284 | $26.7M | No change |
| IVVD Invivyd Inc. | 17.11% | 9,248,250 | $8.1M | No change |
| TGTX TG Therapeutics Inc. | 10.29% | 88,354 | $4.9M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 6.37% | 36,851 | $3.0M | No change |
| GUTS Fractyl Health Inc. | 3.13% | 1,856,117 | $1.5M | No change |
| PRQR Proqr Therapeutics NV | 2.37% | 599,793 | $1.1M | No change |
| SLN Silence Therapeutics PLC-ADR | 2.36% | 101,203 | $1.1M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 1.53% | 210,871 | $721K | No change |
| CRIS Curis Inc. | 0.32% | 284,889 | $149K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| None this quarter. | |||
Portfolio Buys Q1 2026 → Q2 2026
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $47.2M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q1 2026 | 9 | $53.8M | WVE, IVVD, TGTX, ARWR, PRQR |
| Q4 2025 | 9 | $137.6M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q3 2025 | 9 | $68.0M | WVE, IVVD, TGTX, GUTS, ARWR |
| Q2 2025 | 9 | $58.6M | WVE, IVVD, TGTX, GUTS, PRQR |
| Q1 2025 | 11 | $73.0M | WVE, TGTX, IVVD, BBIO, RCKT |
| Q4 2024 | 11 | $101.9M | WVE, TGTX, RCKT, IVVD, SWTX |
| Q3 2024 | 11 | $91.0M | WVE, IVVD, RCKT, GUTS, TGTX |
| Q2 2024 | 11 | $77.1M | WVE, IVVD, RCKT, GUTS, SWTX |
| Q1 2024 | 11 | $135.3M | WVE, IVVD, GUTS, RCKT, SLN |